4D Molecular Therapeutics, Inc. Overview
FDMT market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
FDMT price chart · 1M
- O
- 11.85
- H
- 12.37
- L
- 11.30
- C
- 12.27
- Vol
- 55,798.00
Daily history from Dec 11, 2020
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $11.85
- Previous Close
- $11.26
- Day High
- $12.37
- Day Low
- $11.30
- 52 Week High
- $16.91
- 52 Week Low
- $6.96
- 7 Day Return
- +3.24%
- 30 Day Return
- -2.58%
- 90 Day Return
- +9.70%
- 1 Year Return
- +12.52%
- Daily Notional Volume
- $684.4K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.42 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.96 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -194.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.96 – $16.93 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $621.5M · P/B 0.85 · P/S 6.75.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured